tetano
Editor, Senior Moderator
JNCI Cancer Spectr
. 2021 Jun 29;5(3)
kab049.
doi: 10.1093/jncics/pkab049. eCollection 2021 Jun.
COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors
Austin R Waters[SUP] 1 [/SUP], Deanna Kepka[SUP] 1 2 [/SUP], Joemy M Ramsay[SUP] 1 [/SUP], Karely Mann[SUP] 1 [/SUP], Perla L Vaca Lopez[SUP] 1 [/SUP], John S Anderson[SUP] 1 3 [/SUP], Judy Y Ou[SUP] 1 [/SUP], Heydon K Kaddas[SUP] 1 [/SUP], Alexandra Palmer[SUP] 1 [/SUP], Nicole Ray[SUP] 1 [/SUP], Tomoko Tsukamoto[SUP] 4 [/SUP], Douglas B Fair[SUP] 5 [/SUP], Mark A Lewis[SUP] 4 [/SUP], Anne C Kirchhoff[SUP] 1 6 [/SUP], Echo L Warner[SUP] 7 8 [/SUP]
Affiliations
Abstract
The study objective was to identify sociodemographic and coronavirus disease 2019 (COVID-19) factors that are associated with COVID-19 vaccine hesitancy among adolescent and young adult (AYA) cancer survivors. Eligible participants were 18 years or older and were diagnosed with cancer as an AYA (ages 15-39 years) and received services through an AYA cancer program. A total of 342 participants completed a cross-sectional survey. Our primary outcome-COVID-19 vaccine hesitancy-was surveyed as a 5-point Likert scale and operationalized as a binary outcome (agree vs hesitant). A large proportion of participants reported COVID-19 vaccine hesitancy (37.1%). In the multivariable regression, female survivors (odds ratio = 1.81, 95% confidence interval = 1.10 to 2.98) and survivors with a high school education or less (odds ratio = 3.15, 95% confidence interval = 1.41 to 7.04) reported higher odds of vaccine hesitancy compared with their male or college graduate or higher counterparts. COVID-19 vaccine hesitancy persists among AYA survivors despite their recommended priority vaccination status and higher chances of severe COVID-19 outcomes.
. 2021 Jun 29;5(3)
kab049.doi: 10.1093/jncics/pkab049. eCollection 2021 Jun.
COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors
Austin R Waters[SUP] 1 [/SUP], Deanna Kepka[SUP] 1 2 [/SUP], Joemy M Ramsay[SUP] 1 [/SUP], Karely Mann[SUP] 1 [/SUP], Perla L Vaca Lopez[SUP] 1 [/SUP], John S Anderson[SUP] 1 3 [/SUP], Judy Y Ou[SUP] 1 [/SUP], Heydon K Kaddas[SUP] 1 [/SUP], Alexandra Palmer[SUP] 1 [/SUP], Nicole Ray[SUP] 1 [/SUP], Tomoko Tsukamoto[SUP] 4 [/SUP], Douglas B Fair[SUP] 5 [/SUP], Mark A Lewis[SUP] 4 [/SUP], Anne C Kirchhoff[SUP] 1 6 [/SUP], Echo L Warner[SUP] 7 8 [/SUP]
Affiliations
- PMID: 34195543
- PMCID: PMC8239168
- DOI: 10.1093/jncics/pkab049
Abstract
The study objective was to identify sociodemographic and coronavirus disease 2019 (COVID-19) factors that are associated with COVID-19 vaccine hesitancy among adolescent and young adult (AYA) cancer survivors. Eligible participants were 18 years or older and were diagnosed with cancer as an AYA (ages 15-39 years) and received services through an AYA cancer program. A total of 342 participants completed a cross-sectional survey. Our primary outcome-COVID-19 vaccine hesitancy-was surveyed as a 5-point Likert scale and operationalized as a binary outcome (agree vs hesitant). A large proportion of participants reported COVID-19 vaccine hesitancy (37.1%). In the multivariable regression, female survivors (odds ratio = 1.81, 95% confidence interval = 1.10 to 2.98) and survivors with a high school education or less (odds ratio = 3.15, 95% confidence interval = 1.41 to 7.04) reported higher odds of vaccine hesitancy compared with their male or college graduate or higher counterparts. COVID-19 vaccine hesitancy persists among AYA survivors despite their recommended priority vaccination status and higher chances of severe COVID-19 outcomes.